Stuart Schreiber is co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and has been a member of the National Academy of Sciences since 1995. Dr. Schreiber’s lab integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, especially disease biology, using small molecules and for his role in the development of the field of chemical biology. Key advances include the discoveries of mTOR, histone deacetylases and evidence that chromatin marks regulate gene expression, and small molecules that promote protein–protein interactions. His research has been acknowledged through awards including most recently the Wolf Prize in Chemistry. His approach to therapeutics discovery guided the development of many biotechnology companies including Vertex Pharmaceuticals and Ariad Pharmaceuticals.